Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Persistence of Anti-Hep B Antibodies After Hexaxim or Infanrix Hexa
NCT02610348Completed
- Sponsor
- Sanofi
- Start
- Nov 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Trial of hexaxim in hepatitis B (HBV) (2 arms), sponsored by Sanofi. Primary endpoint: Anti-Hepatitis B antibody concentrations at Day 0. Started Nov 2015; status: completed.
02
Drugs
hexaxim
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02610348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02610348.